The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy

Familial Cancer

Volumn 14, Issue 4, 2015, Pages 539-544

  van der Aa, Jessica E ^a   Hoogendam, Jacob P ^a   Butter, Els S F ^a   Ausems, Margreet G E M ^a   Verheijen, René H M ^a   Zweemer, Ronald P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

BRCA1; BRCA2; Hereditary ovarian cancer; Prophylactic surgery uptake; Risk reducing salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; AGED; ANAMNESIS; ARTICLE; BREAST CANCER; COHORT ANALYSIS; DECISION MAKING; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; OBSERVATIONAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SALPINGOOOPHORECTOMY; THIRD DEGREE RELATIVE; CANCER STAGING; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; MIDDLE AGED; NETHERLANDS; OVARIAN NEOPLASMS; OVARIECTOMY; PATIENT ATTITUDE; PROGNOSIS; PSYCHOLOGY; RISK FACTOR; SALPINGECTOMY; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; OVARIAN NEOPLASMS; OVARIECTOMY; PATIENT ACCEPTANCE OF HEALTH CARE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SALPINGECTOMY;

EID: 84946472280     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-015-9827-7     Document Type: Article

References (35)

1. Antoniou A, Pharoah PD, Narod S, Risch HA et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130
2. Brohet RM, Velthuizen ME, Hogervorst FBL, Meijers-Heijboer HEJ et al (2014) Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet 51:98–107
3. Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ et al (2012) Consortium of Investigators of Modifiers of BRCA1/2. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomark Prev 21(4):645–657
4. King MC, Marks JH (2003) Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646
5. van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, van der Hout AH, Oosterwijk JC (2010) Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 124(3):643–651
6. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P (2006) Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296(2):185–192
7. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609–1615
8. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331–1337
9. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA (2002) Van’t Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616–1622
10. Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, Muzii L, Tombolini V, Panici PB (2014) Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Women’s Health 14:150
11. Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80–87
12. Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collée JM, van Doorn HC, GomezGarcia EB, Kets CM, van Leeuwen FE, Meijers-Heijboer HE, Mourits MJ, van Os TA, Vasen HF, Verhoef S, Rookus MA, Hooning MJ (2015) Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 107(5):812–822
13. Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, van Asperen CJ et al (2006) Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 16(Suppl 1):54–59
14. Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, Burger CW, Brekelmans CT, Mourits MJ, de Bock GH, Gaarenstroom KN, van Boven HH, Mooij TM, Rookus MA (2007) No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 96(9):1335–1342
15. Meeuwissen PA, Seynaeve C, Brekelmans CT, Meijers-Heijboer HJ, Klijn JG, Burger CW (2005) Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 97:476–482
16. Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu JA (2006) Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 94(6):814–819
17. Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M (2006) CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 100(1):20–26
18. Vasen HF, Tesfay E, Boonstra H, Mourits MJ, Rutgers E, Verheijen R et al (2005) Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 41:549–554
19. van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G, Oosterwijk JC, de Bock GH (2009) Time to stop ovarian cancer screening in BRCA1/2 mutation carriers. Int J Cancer 124(4):919–923
20. de Hullu JA, Kets CM, Massuger LF, Ligtenberg ML, van Ham MA, Hoogerbrugge N (2010) Familiaire belasting voor ovariumcarcinoom: beleid. Ned Tijdschr Geneeskd 154:A2392
21. e druk)
22. Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J (2009) Uptake, time course and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomark 13(1):51–56
23. Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White MA, Artioli G, Dudlicek L, Olopade OI (2008) Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med 10(3):161–166
24. Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs JE et al (2014) Use of risk-reducing surgeries in a prospective cohort of 1499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 148:397–406
25. Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD, Brain A, Hopwood P, Howell A (2009) Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomark Prev 18(8):2318–2324
26. Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, Raine-Bennett T, Powell CB (2014) Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol 132(2):428–433
27. Kim D, Kang E, Hwang E, Sun Y, Hwang Y, Yom CK, Kim K, No JH, Kim YB, Kim SW (2013) Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation. Fam Cancer 12(4):621–628
28. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Lubsen-Brandsma L, Massuger LF, Mourits MJ, Gaarenstroom KN, van Dorst EB, van der Putten H, Boonstra H, Aaronson NK (2007) Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol 25(3):301–307
29. Manchanda R, Burnell M, Abdelraheim A, Johnson M, Sharma A, Benjamin E, Brunell C, Saridogan E, Gessler S, Oram D, Side L, Rosenthal AN, Jacobs I, Menon U (2012) Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. BJOG 119(5):527–536
30. Meiser B, Price MA, Butow PN, Karatas J, Wilson J, Heiniger L, Baylock B, Charles M, McLachlan SA, Phillips KA (2013) Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer. Fam Cancer 12(1):101–109
31. Rhiem K, Foth D, Wappenschmidt B, Gevensleben H, Buttner R, Ulrich U, Schmutzler RK (2011) Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 283:623–627
32. Sidon L, Ingham S, Clancy T, Clayton R, Clarke A, Jones EA, Lalloo F, Evans DG (2012) Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. Br J Cancer 106(4):775–779
33. Singh K, Lester J, Karlan B et al (2013) Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol 208:329.e1–329.e6
34. Skytte AB, Gerdes AM, Andersen MK, Sunde L, Brøndum-Nielsen K, Waldstrøm M, Kølvraa S, Crüger D (2010) Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet 77(4):342–349
35. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynaecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23:6890–6898